Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis

@inproceedings{Rossi2013CerebrospinalFD,
  title={Cerebrospinal fluid detection of interleukin-1β in phase of remission predicts disease progression in multiple sclerosis},
  author={Silvia Liliana Rossi and Valeria Studer and Caterina Motta and Giorgio Germani and Giulia Macchiarulo and Fabio Buttari and Raffaele Mancino and Maura Castelli and Valentina De Chiara and Sebastian Weiss and Gianvito Martino and Roberto Furlan and Diego Centonze},
  booktitle={Journal of Neuroinflammation},
  year={2013}
}
BackgroundAbsence of clinical and radiological activity in relapsing–remitting multiple sclerosis (RRMS) is perceived as disease remission. We explored the role of persisting inflammation during remission in disease evolution.MethodsCerebrospinal fluid (CSF) levels of interleukin 1β (IL-1β), a major proinflammatory cytokine, were measured in 170 RRMS patients at the time of clinical and radiological remission. These patients were then followed up for at least 4 years, and clinical, magnetic… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 19 CITATIONS

S100B as a Potential Biomarker and Therapeutic Target in Multiple Sclerosis

  • Molecular Neurobiology
  • 2015
VIEW 11 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Hippocampal neuroplasticity and inflammation: relevance for multiple sclerosis

  • Multiple Sclerosis and Demyelinating Disorders
  • 2017
VIEW 2 EXCERPTS
CITES BACKGROUND

References

Publications referenced by this paper.
SHOWING 1-10 OF 43 REFERENCES

Brain atrophy and lesion load predict long term disability in multiple sclerosis.

  • Journal of neurology, neurosurgery, and psychiatry
  • 2013
VIEW 1 EXCERPT

Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis.

  • Journal of neurology, neurosurgery, and psychiatry
  • 2010
VIEW 1 EXCERPT

Similar Papers